Metformin Versus Placebo from First Trimester to Delivery in Polycystic Ovary Syndrome: A Randomized, Controlled Multicenter Study
Author(s) -
Eszter Vanky,
Solhild Stridsklev,
Runa Heimstad,
Pål Romundstad,
Kristin Skogøy,
Odrun Kleggetveit,
Sissel Hjelle,
Philip von Brandis,
T. Eikeland,
Karin Flo,
Kristin Flaten Berg,
Gabor Bunford,
Agnethe Lund,
Cecilie Bjerke,
Ingunn Almås,
Ann Hilde Berg,
Anna Danielson,
Gulim Lahmami,
Sven M. Carlsen
Publication year - 2010
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2010-0853
Subject(s) - polycystic ovary , medicine , metformin , pregnancy , placebo , gestational diabetes , preeclampsia , obstetrics , randomized controlled trial , placebo controlled study , gynecology , diabetes mellitus , gestation , endocrinology , insulin resistance , double blind , alternative medicine , pathology , biology , genetics
Metformin is widely prescribed to pregnant women with polycystic ovary syndrome (PCOS) in an attempt to reduce pregnancy complications. Metformin is not approved for this indication, and evidence for this practice is lacking.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom